sr141716 has been researched along with Degenerative Diseases, Central Nervous System in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bifulco, M; Gazzerro, P; Grimaldi, C; Pisanti, S; Santoro, A | 1 |
| Azcoitia, I; Fernández-Ruiz, J; García-Segura, LM; Hansen, HH; Hansen, HS; Pons, S; Ramos, JA; Romero, J | 1 |
1 review(s) available for sr141716 and Degenerative Diseases, Central Nervous System
| Article | Year |
|---|---|
Rimonabant: just an antiobesity drug? Current evidence on its pleiotropic effects.
Topics: Anti-Obesity Agents; Antineoplastic Agents; Body Weight; Humans; Neurodegenerative Diseases; Obesity; Piperidines; Pyrazoles; Receptor, Cannabinoid, CB1; Rimonabant; Smoking Cessation; Substance-Related Disorders | 2007 |
1 other study(ies) available for sr141716 and Degenerative Diseases, Central Nervous System
| Article | Year |
|---|---|
Blockade of cannabinoid CB(1) receptor function protects against in vivo disseminating brain damage following NMDA-induced excitotoxicity.
Topics: Animals; Benzoxazines; Brain; Cannabinoids; Cell Survival; Cerebral Cortex; Corpus Striatum; Morpholines; N-Methylaspartate; Naphthalenes; Neurodegenerative Diseases; Neurotoxins; Parietal Lobe; Piperidines; Pyrazoles; Rats; Rats, Sprague-Dawley; Receptor, Cannabinoid, CB2; Receptors, Cannabinoid; Receptors, Drug; Rimonabant | 2002 |